Publication: Consensus-based clinical recommendations and research priorities for anticoagulant thromboprophylaxis in children hospitalized for COVID-19–related illness
Submitted Date
Received Date
Accepted Date
Issued Date
2020-11-01
Copyright Date
Announcement No.
Application No.
Patent No.
Valid Date
Resource Type
Edition
Resource Version
Language
File Type
No. of Pages/File Size
ISBN
ISSN
15387836
15387933
15387933
eISSN
Scopus ID
WOS ID
Pubmed ID
arXiv ID
Call No.
Other identifier(s)
2-s2.0-85094869393
Journal Title
Volume
Issue
item.page.oaire.edition
Start Page
End Page
Access Rights
Access Status
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Physical Location
Bibliographic Citation
Journal of Thrombosis and Haemostasis. Vol.18, No.11 (2020), 3099-3105
Citation
Neil A. Goldenberg, Anthony Sochet, Manuela Albisetti, Tina Biss, Mariana Bonduel, Julie Jaffray, Graeme MacLaren, Paul Monagle, Sarah O’Brien, Leslie Raffini, Shoshana Revel-Vilk, Nongnuch Sirachainan, Suzan Williams, Ayesha Zia, Christoph Male (2020). Consensus-based clinical recommendations and research priorities for anticoagulant thromboprophylaxis in children hospitalized for COVID-19–related illness. Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/60036.
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Consensus-based clinical recommendations and research priorities for anticoagulant thromboprophylaxis in children hospitalized for COVID-19–related illness
Alternative Title(s)
Author's Affiliation
Author's E-mail
Editor(s)
Editor's Affiliation
Corresponding Author(s)
Creator(s)
Compiler
Advisor(s)
Illustrator(s)
Applicant(s)
Inventor(s)
Issuer
Assignee
Other Contributor(s)
Nationwide Children’s Hospital
Hebrew University-Hadassah Medical School
National University Hospital, Singapore
University of Melbourne
Royal Children's Hospital, Melbourne
University of Toronto Faculty of Medicine
Faculty of Medicine, Ramathibodi Hospital, Mahidol University
Keck School of Medicine of USC
UT Southwestern Medical School
Medizinische Universitat Wien
Murdoch Children's Research Institute
University of Pennsylvania Perelman School of Medicine
Kinderspital Zürich
All Children's Hospital St. Petersburg
Fundacion Hospital de Pediatria Professor Dr. Juan P. Garrahan
The Newcastle Upon Tyne Hospitals NHS Foundation Trust
Johns Hopkins School of Medicine
Hebrew University-Hadassah Medical School
National University Hospital, Singapore
University of Melbourne
Royal Children's Hospital, Melbourne
University of Toronto Faculty of Medicine
Faculty of Medicine, Ramathibodi Hospital, Mahidol University
Keck School of Medicine of USC
UT Southwestern Medical School
Medizinische Universitat Wien
Murdoch Children's Research Institute
University of Pennsylvania Perelman School of Medicine
Kinderspital Zürich
All Children's Hospital St. Petersburg
Fundacion Hospital de Pediatria Professor Dr. Juan P. Garrahan
The Newcastle Upon Tyne Hospitals NHS Foundation Trust
Johns Hopkins School of Medicine
Series
Has Part
Abstract
© 2020 International Society on Thrombosis and Haemostasis Background: Observational studies indicate that children hospitalized with COVID-19-related illness, like adults, are at increased risk for venous thromboembolism (VTE). A multicenter phase 2 clinical trial of anticoagulant thromboprophylaxis in children hospitalized with COVID-19-related illness has recently been initiated in the United States. To date, there remains a paucity of high-quality evidence to inform clinical practice world-wide. Therefore, the objective of this scientific statement is to provide consensus-based recommendations on the use of anticoagulant thromboprophylaxis in children hospitalized for COVID-19-related illnesses, and to identify priorities for future research. Methods: We surveyed 20 pediatric hematologists and pediatric critical care physicians from several continents who were identified by Pediatric/Neonatal Hemostasis and Thrombosis Subcommittee leadership as having experience and expertise in the use of anticoagulant thromboprophylaxis and/or the management of COVID-19-related illness in children. A comprehensive review of the literature on COVID-19 in children was also performed. Results: Response rate was 90%. Based on consensus of expert opinions, we suggest the administration of low-dose low molecular weight heparin subcutaneously twice-daily as anticoagulant thromboprophylaxis (in the absence of contraindications, and in combination with mechanical thromboprophylaxis with sequential compression devices, where feasible) in children hospitalized for COVID-19-related illness (including the multisystem inflammatory syndrome in children [MIS-C]) who have markedly elevated D-dimer levels or superimposed clinical risk factors for hospitalassociated VTE. For children who are clinically unstable or have severe renal impairment, we suggest the use of unfractionated heparin by continuous intravenous infusion as anticoagulant thromboprophylaxis. In addition, continued efforts to characterize VTE risk and risk factors in children with COVID-19, as well as to evaluate the safety and efficacy of anticoagulant thromboprophylaxis strategies in children hospitalized with COVID-19-related illness (including MIS-C) via cooperative multicenter trials, were identified among several key priorities for future research. Conclusion: These consensus-based recommendations on the use of anticoagulant thromboprophylaxis in children hospitalized for COVID-19-related illnesses and priorities for future research will be updated as high-quality evidence emerges.